Compare Allstate Corp (ALL) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs Danaher Corporation — how do they compare? Allstate Corp trades at $251.71 (market cap $64.77B), while Danaher Corporation trades at $199.06 (market cap $140.88B). The key difference: Danaher Corporation is far larger — about 2.2× Allstate Corp's market cap, and Allstate Corp pays the higher dividend (1.72%). Which is the better fit depends on your goals.
| ALL | DHR | |
|---|---|---|
Market Cap | $64.77B | $140.88B |
Sector | Financials | Health |
52-Week High | $251.61 | $242.05 |
52-Week Low | $190.00 | $161.91 |
Enterprise Value | $73.56B | $153.66B |
Dividend Yield | 1.72% | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $251.61, up 1.19% on the day, with a bullish technical outlook and strong fundamental momentum. The stock shows robust earnings beats in recent quarters, a low P/E of 5.57, and a high ROE of 48.44%. Recent news highlights dividend declarations and anticipation for Q2 2026 earnings, with analysts citing improved underwriting and catastrophe performance as key drivers.
The outlook remains positive given valuation discounts and earnings growth, but risks include hurricane season exposure and competitive pressures. Upside potential is supported by a consensus price target of $251.18, with Wall Street largely holding a buy or neutral stance, though near-term volatility may arise from earnings results due August 6, 2026.
Danaher (DHR) trades at $199.05, up 1.57% on the day, with a bullish technical signal and strong analyst support. The stock has beaten earnings estimates for three consecutive quarters, though revenue growth remains modest and profit margins have compressed from pandemic peaks. Recent business developments include the shareholder approval of the Masimo acquisition and new product launches in its SCIEX division, suggesting ongoing strategic investment.
The outlook is cautiously optimistic, supported by a dominant 'Buy' analyst consensus and a price target implying ~7% upside. Key opportunities lie in the firm's biotechnology segment strength and strategic M&A. Risks include ongoing margin pressure, integration challenges from acquisitions, and a relatively high valuation (P/E of 38.6) that demands sustained earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
